Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment | MicrobiomeTrials← Back to trialsNCT07304154
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-04-10Est. Completion: 2029-06
Enrollment target: 57 participants Locations- Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
- Stanford Neuroscience Health Center, Palo Alto, California, United States
- Columbia University Irving Medical Center, New York, New York, United States
- LDS Hospital - Intermountain Health, Salt Lake City, Utah, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- Concord Repatriation General Hospital, Sydney, New South Wales, Australia
- Corner Hawkesbury Road and Darcy Road, Westmead, New South Wales, Australia
- Centre Intégré Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont, Montreal, Canada
- Jewish General Hospital, Montreal, Canada
- The Ottawa Hospital - General Campus, Ottawa, Canada
Other microbiome trials you might be interested in
B-cell Mediated Autoimmune Disorders
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-c…
La Jolla, United StatesEst. completion Dec 1, 2026
Chronic Inflammatory Demyelinating PolyneuropathyCIDPChronic Inflammatory Demyelinating Polyradiculoneuropathy
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study…
Birmingham, United StatesEst. completion Oct 7, 2027
Polyneuropathy, Inflammatory Demyelinating, Chronic
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-t…
Homewood, United StatesCompleted Oct 3, 2029